Andrew Wilson is a Respiratory physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3366 Oakdale Ave N Ste 605
Respiratory Consultants, Pa
Robbinsdale, MN 554225700
Telephone
763-520-2940Registry record last updated 7 Jul 2015.
Clinical trials
- Poly-unsaturated Fats for Improving Nasal Polyps and Asthma
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
- Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
- Asthma Breath Biomarker Assessment
Sponsor: University of East Anglia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Edwards Lifesciences CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
64.6%Corticosteroid32.5%Trelegy Ellipta38%Fluticasone Propionate28%Breo Ellipta22%Budesonide-Formoterol Fumarate9%Qvar Redihaler3%Part D<11 patientsbeta2-Adrenergic Agonist13.7%Albuterol Sulfate Hfa80%Ventolin Hfa20%Part D≥42 patients+ 4 more classes in this area
Metabolism & gastrointestinal
17.2%Corticosteroid12.7%Prednisone100%Part D≥51 patientsProton pump inhibitor4.5%Omeprazole100%Part D≥17 patientsAnti-infectives
12.8%Macrolide Antimicrobial9.4%Azithromycin100%Part D≥33 patientsTetracycline-class Drug3.4%Doxycycline Hyclate100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”